BeOne Medicines (BeiGene) 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 total revenue was $1.9 billion, compared with $1.4 billion in the prior year, and product revenue grew 33% year over year to approximately $1.9 billion.
- Brukinza global revenue reached approximately $1.4 billion, up 34% year over year; U.S. sales exceeded $1 billion for the first time and grew 36%, including an approximate $50 million tailwind from order timing and an extra shipping day.
- Tevimbra generated approximately $243 million, up 28% year over year, while the Amgen in-license portfolio generated approximately $167 million, up 26%.
- Revenue was approximately $1 billion in the U.S., $527 million in China, $234 million in Europe, and $80 million in rest of world markets; reported China growth of 21% included a 7% foreign-exchange contribution.
- GAAP gross margin was approximately 88%; operating expenses were approximately $1.25 billion, income from operations was $419 million, and net income was $385 million.
- GAAP diluted earnings per ADS were $3.28, compared with $1.09 in the prior period; adjusted income from operations was $612 million, adjusted net income was $539 million, and adjusted diluted earnings per ADS were $4.59, compared with $2.65 a year ago.
- Free cash flow increased 34% year over year to $474 million.
- Clinical and development progress included complete submissions for Opokinser in treatment-naive mantle cell lymphoma in the U.S., Europe, and China, FDA priority review, and progress across five late-stage solid tumor programs.
- At ESMO, the GPC3/4-1BB bispecific showed a 36% confirmed response rate in heavily pretreated HCC, with a 6-month duration of response rate of approximately 79%; the brain-penetrant PRMT5 inhibitor showed a 38.5% confirmed response rate in previously treated mTAP-deficient EGFR wild-type non-small cell lung cancer, with median PFS of 8.1 months; and the CEADC showed a 60% confirmed response rate in heavily pretreated non-small cell lung cancer.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, everyone. Welcome to BeOne Medicines Q3 2026 earnings call webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. At this time, I would like to turn the call over to the company.
Hello and welcome. Thanks for joining us today. I'm Dan Maller, Head of Investor Relations at BeOne Medicines. Before we begin, please note that you can find additional materials, including a replay of today's webcast and presentation on the investor relations section of our website, ir.beonemedicines.com. I would like to remind all participants that during this call, we may make forward-looking statements regarding, among other things, the company's future prospects and business strategy. Actual results may differ materially from those indicated in the forward-looking statements as a result of various factors, including those risks discussed in our most recent periodic report filed with the SEC. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation.
Reconciliations between GAAP and non-GAAP financial measures discussed on this call are provided in the appendix to our presentation, which is posted to our investor relations website along with our earnings release. All information in this presentation is as of the date of the presentation, and we undertake no duty to update such information unless required by law. Now turning to today's call as outlined on slide three. John Oyler, our Co-Founder, Chairman, and CEO, will provide a business update. Aaron Rosenberg, our CFO, will provide an update on our third quarter financial results and 2026 financial guidance. Lai Wang, President and Global Head of R&D, will discuss our R&D and pipeline progress. We will then open the call to questions.
Joining the team for the Q&A portion of the call will be Xiaobin Wu, President and Chief Operating Officer, Matt Shaulis, our General Manager of North America, Mark Lanasa, Chief Medical Officer for Solid Tumors, and Amit Agarwal, Chief Medical Officer for Hematology. I'll now pass the call over to John.
John? Thank you, Dan, and welcome.
I am pleased to present our Q3 results today. Across every dimension of the business, BeOne is executing at the very highest level in our history. The results speak for themselves. Financially, we continue to deliver rapid growth and strong earnings. Aaron will take you through that shortly. In hematology, BRUKINSA's powerful and sustained BTK inhibition continues to translate into clinical and real-world differentiation. Building on BRUKINSA, BEQALZI, and tacabrutideg are expanding our leadership and extending it well into the future. In solid tumors, we are living up to our promise that 2026 would be an inflection year. Last week, we shared data for three of our most promising programs at ESMO. We have now shared differentiated data for five pivotal late-stage solid tumor programs.
We have reached a level of productivity that I think is very rare in our industry, and the model we have worked so hard to build is already delivering very tangible results, and we have only just begun to scratch the surface of what is possible. Here we see BRUKINSA's performance for the quarter. Sales totaled $1.4 billion, growing 34% year-over-year, with U.S. sales exceeding $1 billion for the quarter for the first time. The underlying fundamentals continue to be very strong. BRUKINSA is not just a leader in CLL. It is a powerful treatment option across four other B-cell malignancies, and we are far from done. BRUKINSA, both as a single agent and in combination, continues to generate the most phase III data across the BTKI class. We often talk about BRUKINSA's clinical differentiation.
It was designed for complete and sustained BTK inhibition, and it remains the only CLL therapy to show PFS superiority over ibrutinib in a head-to-head trial. The results we see in the clinical trial data for BRUKINSA are increasingly reinforced in the real world, and the picture is remarkably consistent. This slide brings together six independent data sets in CLL, representing tens of thousands of patients across three endpoints: overall survival, time to discontinuation, and time to next treatment. Across all of it, the answer is the same. All 21 hazard ratios favor BRUKINSA. In overall survival versus acalabrutinib, the four large U.S. claims data sets, including Medicare, range from 16%-25% lower risk of death. Versus ibrutinib, the reduction was 27%-36%.
Taken together across U.S. and European patients, claims and health records, survival and treatment durability, and versus both acalabrutinib and ibrutinib, the real-world evidence consistently favors BRUKINSA. BRUKINSA has established a strong foundation in hematology, but it is only the beginning of what we believe our heme franchise can achieve. With BRUKINSA, BEQALZI, and tacabrutideg, we are the only company with potentially best-in-class medicines across the three key mechanisms of action in B-cell malignancies. So whether a patient wants continuous or fixed-duration therapy, or requires an option after progression, we will be able to meet the need with the right medicine, alone or in combination. No other company is positioned to do that. This is not hypothetical. In the pivotal trials for the regimens on this slide, they are already reading out, and the data will be coming fast and furious over the next three years.
Behind these three promising medicines, the next wave of heme assets from our prolific discovery engine is entering the clinic. This includes small molecules, multispecific antibodies, and novel cell therapies. Turning to solid tumors, over the past several months, we have shared differentiated data for five programs: our GPC3 x 4-1BB bispecific antibody, our brain penetrant PRMT5 inhibitor, our CEA ADC, our CDK4 inhibitor, and our B7-H4 ADC. Most companies have just one exciting asset. Some have two. From just the first wave of our solid tumor pipeline, we have five, all advancing towards registration-enabling development in roughly the same time. These programs target some of the most common and deadly cancers in the world, including lung, breast, liver, gastric, and ovarian cancer. Together, they affect millions of patients every year and account for millions of cancer deaths worldwide.
When we started this company 16 years ago, the goal was simple: to fight cancer and to fight for life, and also to dramatically change how things were done in our industry by building a company that could sustain that purpose. Today, that is no longer a vision, it is a reality. How are we doing this? This slide reiterates something fundamentally different about BeOne. For years, we have talked about our goal to build a lasting oncology company, one that generates higher returns for each dollar of R&D investment by leveraging our global development superhighway. Today, we are seeing the results. Over the last three years, we have brought more new oncology medicines into the clinic than any other company in our industry. We are moving them through the clinic with exceptional speed, behind the power of our global development superhighway.
Our CDK4 inhibitor and B7-H4 ADC programs show what this looks like in practice. Both moved from first in human to pivotal development in just two and a half years, allowing us to rapidly close the gap with the competition. Now we are seeing that pipeline advance into registrational trials, which puts BeOne in an exceptionally select group of oncology innovators. If you look back at any 18-month period in oncology since 2010, very few companies have ever seen this level of late-stage productivity. Our peers on this list are the largest, most accomplished pharma companies in the world, with R&D budgets many times ours. Yet, there we are, among the top. Our scientists are generating more high-quality shots on goal, we are advancing them faster, and importantly, we are converting them into late-stage programs. We are just getting started. At BeOne, we believe we have created something truly special.
I just want to thank the team again for doing this. After these years of sustained investment and hard work, we have certainly built a model that is unique in the industry and is extremely difficult to replicate. It is built on four competitive advantages: rigorous and prolific internal research, our global development superhighway, global commercial presence, and an entrepreneurial culture driven by a deep sense of urgency, because cancer patients just cannot wait. These advantages create a self-reinforcing feedback loop. Together, they enable us to drive industry-leading R&D returns at scale, turn that innovation into profitable growth, and to fund a growing level of investment in next-generation medicines. Each turn of the cycle strengthens the next. That compounding effect is BeOne’s greatest long-term competitive advantage, and the best way to maximize long-term value is to keep investing behind it.
As Aaron Rosenberg will discuss later, we think it's important to retain the financial flexibility to fully fund the opportunities we see in the business. We believe this is the right approach to bring more transformative medicines to patients and to achieve our goal of building the world's leading oncology company. With that, I'll turn it over to Aaron Rosenberg to discuss our financial performance.
Aaron Rosenberg. Thanks, John Oyler.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
